Dominant‐negative inhibition of PRC2 activity by recurrent H3K27 mutations drives the development of paediatric glioma 17, and EZH2‐deficient mice show accelerated and more aggressive development of myc‐driven medulloblastoma 18. This evidence concerns the gene EZH2 and central nervous system cancer.